LMR Partners LLP Purchases New Shares in DexCom, Inc. (NASDAQ:DXCM)

LMR Partners LLP acquired a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 153,324 shares of the medical device company's stock, valued at approximately $11,924,000.

A number of other large investors also recently modified their holdings of the company. Czech National Bank raised its stake in DexCom by 3.7% in the fourth quarter. Czech National Bank now owns 84,689 shares of the medical device company's stock valued at $6,586,000 after purchasing an additional 3,057 shares in the last quarter. Capital Investment Advisors LLC bought a new stake in DexCom in the fourth quarter valued at $206,000. CHICAGO TRUST Co NA boosted its holdings in DexCom by 67.9% in the fourth quarter. CHICAGO TRUST Co NA now owns 18,236 shares of the medical device company's stock valued at $1,418,000 after acquiring an additional 7,373 shares in the last quarter. Cullen Investment Group LTD. boosted its holdings in DexCom by 5.6% in the fourth quarter. Cullen Investment Group LTD. now owns 11,502 shares of the medical device company's stock valued at $895,000 after acquiring an additional 614 shares in the last quarter. Finally, 180 Wealth Advisors LLC bought a new stake in DexCom in the fourth quarter valued at $255,000. 97.75% of the stock is currently owned by institutional investors.

DexCom Stock Performance

Shares of NASDAQ:DXCM traded down $0.19 during trading on Friday, hitting $85.48. 3,397,377 shares of the stock traded hands, compared to its average volume of 4,356,519. The company has a quick ratio of 1.28, a current ratio of 1.47 and a debt-to-equity ratio of 0.59. The company has a market cap of $33.52 billion, a price-to-earnings ratio of 59.78, a P/E/G ratio of 2.30 and a beta of 1.43. The company has a fifty day moving average price of $72.01 and a two-hundred day moving average price of $77.60. DexCom, Inc. has a 52-week low of $57.52 and a 52-week high of $132.26.

DexCom (NASDAQ:DXCM - Get Free Report) last released its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The company had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period in the prior year, the business posted $0.32 EPS. DexCom's revenue was up 12.5% compared to the same quarter last year. As a group, equities analysts predict that DexCom, Inc. will post 2.03 EPS for the current year.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. Canaccord Genuity Group lifted their price target on shares of DexCom from $103.00 to $106.00 and gave the company a "buy" rating in a report on Friday, May 2nd. Redburn Atlantic upgraded shares of DexCom from a "neutral" rating to a "buy" rating and boosted their target price for the company from $85.00 to $115.00 in a report on Monday, February 3rd. Robert W. Baird dropped their target price on shares of DexCom from $115.00 to $105.00 and set an "outperform" rating on the stock in a report on Friday, May 2nd. Morgan Stanley boosted their target price on shares of DexCom from $75.00 to $82.00 and gave the company an "equal weight" rating in a report on Friday, February 14th. Finally, Mizuho started coverage on shares of DexCom in a research note on Thursday, April 10th. They issued an "outperform" rating and a $85.00 price target on the stock. Five investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat.com, DexCom currently has a consensus rating of "Moderate Buy" and an average price target of $98.11.

Insiders Place Their Bets

In other news, EVP Jereme M. Sylvain sold 7,000 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $73.83, for a total transaction of $516,810.00. Following the transaction, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Jacob Steven Leach sold 14,076 shares of the company's stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total transaction of $990,668.88. Following the completion of the transaction, the chief operating officer now directly owns 313,497 shares in the company, valued at $22,063,918.86. The trade was a 4.30% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 66,926 shares of company stock valued at $4,734,384 in the last 90 days. 0.32% of the stock is owned by insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.